Page 5 - Anjali Singh

Biosimilars could surpass generics in US mkt by early 2030s: Dr Reddy's CEO

Dr Reddy's CEO Erez Israeli says semaglutide, biosimilars and oncology will drive the company's next growth phase as it expands beyond traditional generics globally

Cancer care expands beyond metros as providers bet on tier-2, tier-3 India

Hospitals, diagnostics firms, and support groups are expanding cancer care into tier-2 and tier-3 cities as demand, screening and awareness rise beyond large metros

RPG Group on PM Modi's call for restraint: WFH, cleaner mobility

Harsh Goenka says the conglomerate is expanding remote work, limiting travel and accelerating electric mobility adoption amid West Asia tensions

India's electric bus push gains speed amid strong market recovery: Report

KPMG report says government schemes, rising urban mobility demand and improving economics are accelerating growth in India's electric bus market

Cipla Q4 profit plunges 55% to ₹554.6 cr amid US drag, higher R&D spend

Drugmaker cites lower contribution from key US products, higher R&D investments and rising operating costs as Q4 FY26 profit declines sharply

Asia Healthcare Holdings appoints three independent directors to board

GIC and TPG-backed Asia Healthcare Holdings has inducted three independent directors as it expands its specialty healthcare network across India

PM Modi's EV push lifts industry confidence, but policy gaps persist

India's EV industry sees stronger momentum after Prime Minister Narendra Modi renewed his push for electric mobility amid rising sales and infrastructure growth

West Asia tensions begin disrupting India's auto supply chain, margins

Bajaj Auto, Hero MotoCorp and Ather Energy flag rising commodity prices, freight costs and supply-chain disruptions as geopolitical tensions weigh on demand and margins

Biocon eyes in-licensing opportunities to expand biosimilars portfolio

Biocon is scouting for biosimilar in-licensing opportunities while banking on multiple FY27 product launches to drive growth, margins, and market expansion

Bharat Forge Q4 results: Net profit falls 17.5% on labour code impact

Bharat Forge reported a 17.5 per cent decline in Q4 net profit due to labour code-related charges and expects around 25 per cent revenue growth in FY27

Mahindra group appoints Vimal Agarwal as group chief internal auditor

Mahindra Group has appointed Vimal Agarwal as Group Chief Internal Auditor from July 1, 2026, as the conglomerate sharpens its focus on governance and internal controls

India electric vehicle sales surge in April as passenger vehicles jump 75%

India's electric vehicle market recorded strong annual growth in April 2026, led by a sharp rise in passenger vehicle sales and broader consumer adoption

Emcure Pharmaceuticals Q4 results: Profit jumps 28%, revenue up by 16%

The rise in profits was attributed to the robust performance in international markets and growth in new launches from Emcure's in-house portfolio

West Bengal election results: Industrialists pin hopes on BJP's win

Strained Centre-state relations had long made investors wary, a sentiment reinforced by Trinamool leader Mamata Banerjee's rise on the back of a land agitation in Singur and Nandigram

Ather Energy Q4 loss narrows on strong volume growth, revenue rises sharply

The company posted a net loss of ₹100.2 crore in Q4 FY26, compared with a loss of ₹234.3 crore in the year-ago period

Despite a strong March, electric vehicle makers keep discounts high

Aggressive discounting persists in the EV market as automakers juggle inventory, competition, and evolving buyer expectations

Aster DM Healthcare Q4FY26 net profit jumps 77%; revenue rises 18%

Strong growth in hospitals, clinics and labs drives earnings; margins expand on operating leverage and cost discipline across key regional clusters

Castrol India banks on pricing, rural push to navigate cost pressures

Castrol India is relying on price hikes and rural expansion to offset rising costs, while sustaining growth through steady demand and market share gains across segments

Piramal Pharma bets on FY27 rebound; expects mid-teens growth, margin gains

Piramal Pharma expects a recovery in FY27 with mid-teens revenue growth and improved margins, supported by CDMO rebound, stronger order inflows, and global supply chain shifts

Ceat Q4 profit more than doubles on global push, revenue rises 23%

Tyre maker posts strong earnings on international growth and improved mix, but flags near-term margin pressure from rising raw material costs